Clinical Implications of Plasmodium vivax Malaria

Plasmodium vivax is the most geographically widespread human malaria parasite. While historically considered benign, mounting evidence indicates it can cause severe anaemia, respiratory distress and other life-threatening complications. Its unique biology, notably dormant liver stages, underpins recurrent relapses that exacerbate morbidity, particularly among young children, pregnant women and immunologically naïve travellers. Symptoms often include fever, chills and malaise but may progress to severe anaemia, thrombocytopenia and multi-organ dysfunction. Repeated relapses drive cumulative blood-stage parasite biomass and heighten the risk of complications. Management demands prompt diagnosis, effective blood-stage treatment and radical cure to eliminate dormant hypnozoites. However, patient safety hinges on screening for glucose-6-phosphate dehydrogenase deficiency before prescribing primaquine or tafenoquine. Emerging evidence of reduced drug susceptibility and the parasite’s capacity to evade immune detection further complicates control efforts and underscores the need for improved diagnostics, surveillance and therapeutic strategies on a global scale.

Research from Nature Portfolio

Recent studies have characterised the dynamics of Plasmodium vivax lactate dehydrogenase (PvLDH), a key enzyme released during parasite development. Novel mathematical models integrating ex vivo and clinical data reveal that PvLDH accumulates rapidly in late ring stages, peaks 10–20 hours post-invasion and has an in vivo half-life of around 22 hours. These quantitative insights refine estimates of total parasite biomass in vivax malaria, demonstrating that standard microscopy often underestimates the hidden infection load. Such advances pave the way for optimised PvLDH-based diagnostic assays and more accurate monitoring of treatment efficacy, thereby enhancing the capacity to detect low-density infections and guide targeted interventions.

Clinical Implications of Plasmodium vivax Malaria publication trend

The graph below shows the total number of articles in clinical implications of plasmodium vivax malaria across all publications each year (not limited to Nature Index journals).

Technical terms

Hypnozoite: Dormant liver stage of P. vivax that can reactivate and cause relapses.

Radical cure: Therapeutic regimen targeting both blood-stage parasites and dormant hypnozoites to prevent recurrence.

Parasite biomass: Total mass of parasitic organisms within the host, including visible and hidden compartments.

Glucose-6-phosphate dehydrogenase deficiency: Genetic condition affecting red blood cell enzyme activity, predisposing to haemolysis with certain antimalarials.

References

1. Characterisation of Plasmodium vivax lactate dehydrogenase dynamics in P. vivax infections. Communications Biology (2024).
2. Clinical impact of vivax malaria: A collection review. PLOS Medicine (2022).
3. Vivax malaria: a possible stumbling block for malaria elimination in India. Frontiers in Public Health (2024).